Zenas BioPharma (ZBIO) Stock Price, News & Analysis

Company Overview

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business.

Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.

The company is led by co-founder and Chief Executive Officer Hua Mu, who has experience in the biopharmaceutical industry. Zenas’s development efforts are aimed at patients with immune-mediated diseases for which existing treatment options may be limited.

Key Stats

• Today's Range: $27.42 to $28.75
• 50-Day Range: $24.84 to $33.13
• 52-Week Range: $13.50 to $44.60
• Volume: 484,892 shs
• Average Volume: 782,656 shs
• Market Capitalization: $1.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.71
• Consensus Rating: Moderate Buy

Zenas BioPharma Stock Analysis - MarketRank™

Zenas BioPharma scored higher than 61% of companies evaluated by MarketBeat, and ranked 366th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zenas BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Zenas BioPharma has a consensus price target of $46.71, representing about 66.4% upside from its current price of $28.07.

Amount of Analyst Coverage

Zenas BioPharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zenas BioPharma are expected to grow in the coming year, from ($6.23) to ($4.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zenas BioPharma is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zenas BioPharma is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zenas BioPharma has a P/B Ratio of 8.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.33% of the float of Zenas BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Zenas BioPharma has a short interest ratio ("days to cover") of 24.08, which indicates bearish sentiment.

Change versus previous month

Short interest in Zenas BioPharma has recently decreased by 9.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zenas BioPharma does not currently pay a dividend.

Dividend Growth

Zenas BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.29

News Sentiment

Zenas BioPharma has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Zenas BioPharma this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for ZBIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zenas BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.00% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Zenas BioPharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/12/2026
• Jefferies Global Healthcare Conference: 11/16/2026
• Next Earnings (Estimated): 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZBIO
• Previous Symbol: NASDAQ:ZBIO
• CIK: 1953926
• Web: zenasbio.com
• Phone: (857) 271-2954
• Fax: N/A
• Employees: 167
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Zenas BioPharma: $46.71
• High Price Target: $55.00
• Low Price Target: $32.00
• Potential Upside/Downside: +68.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$377.74 million
• Net Margins: N/A
• Pretax Margin: -4,923.08%
• Return on Equity: -144.65%
• Return on Assets: -59.83%

Debt

• Debt-to-Equity Ratio: 1.88
• Current Ratio: 9.42
• Quick Ratio: 9.93

Sales & Book Value

• Annual Sales: $10 million
• Price / Sales: 188.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.13 per share
• Price / Book: 8.88

Miscellaneous

• Outstanding Shares: 67,820,000
• Free Float: 52,898,000
• Market Cap: $1.88 billion
• Optionable: Optionable
• Beta: -0.88